Holen Sie sich die Stockscreener-App
3.89
1.77%
-0.07
Handel nachbörslich:
3.89
Schlusskurs vom Vortag:
$3.96
Offen:
$3.95
24-Stunden-Volumen:
345.12K
Relative Volume:
0.48
Marktkapitalisierung:
$129.14M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-86.60M
KGV:
-1.3734
EPS:
-2.8324
Netto-Cashflow:
$-67.37M
1W Leistung:
-5.58%
1M Leistung:
-0.51%
6M Leistung:
-20.61%
1J Leistung:
-66.29%
1-Tages-Spanne:
$3.86
$4.01
1-Wochen-Bereich:
$3.86
$4.40
52-Wochen-Spanne:
$1.45
$13.63
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Firmenname
Lexeo Therapeutics Inc
Sektor
Branche
Telefon
(212) 547-9879
Adresse
345 PARK AVENUE SOUTH, NEW YORK
Vergleichen Sie LXEO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
3.89 | 222.41M | 0 | -86.60M | -67.37M | -2.8324 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-06-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-11-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-11-28 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-28 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-11-28 | Eingeleitet | Stifel | Buy |
Alle ansehen
Lexeo Therapeutics Inc Aktie (LXEO) Neueste Nachrichten
What analysts say about Lexeo Therapeutics Inc. stockFree Daily Trading Room Entry - Autocar Professional
Lexeo Therapeutics Inc. Stock Analysis and ForecastHigh-return market picks - jammulinksnews.com
What drives Lexeo Therapeutics Inc. stock priceTremendous financial leverage - jammulinksnews.com
Is Lexeo Therapeutics Inc. a good long term investmentRapid wealth accumulation - jammulinksnews.com
Will Lexeo Therapeutics Inc. stock split in the near futureSafe and Smart Investment Picks - beatles.ru
Lexeo Therapeutics (NASDAQ:LXEO) & Organogenesis (NASDAQ:ORGO) Head to Head Analysis - Defense World
What analysts say about Lexeo Therapeutics Inc. stock outlookFree Investment Portfolio Suggestions - Newser
How high can Lexeo Therapeutics Inc. stock price go in 2025Safe and Smart Investment Picks - Newser
What makes Lexeo Therapeutics Inc. stock price move sharplyFree Access to Community with 300% Return - beatles.ru
Why Lexeo Therapeutics Inc. stock attracts strong analyst attentionFree Expert-Led Investment Training - Newser
How Lexeo Therapeutics Inc. stock performs during market volatilityCarefully Curated High Return Stocks - Newser
Lexeo Therapeutics soars 96% following March Fair Value signal By Investing.com - Investing.com South Africa
Lexeo Therapeutics soars 96% following March Fair Value signal - Investing.com
Stifel reiterates Buy rating on Lexeo Therapeutics stock at $21 price target - Investing.com Nigeria
Stifel reiterates Buy rating on Lexeo Therapeutics stock at $21 price target By Investing.com - Investing.com South Africa
Lexeo Therapeutics stock rises after FDA breakthrough designation By Investing.com - Investing.com Nigeria
Lexeo Therapeutics Secures FDA Breakthrough Therapy Designation for LX2006, Shares Rise 8% in Pre-market Trade. - AInvest
Lexeo Therapeutics announces FDA Breakthrough Therapy Designation for LX2006 - TipRanks
Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia Treatment - Nasdaq
FDA grants breakthrough therapy designation to Lexeo’s FA treatment - Investing.com
Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia - GlobeNewswire
FDA Breakthrough: Lexeo's Gene Therapy Shows Promise in Fatal Rare Disease Treatment - Stock Titan
FDA grants breakthrough therapy designation to Lexeo’s FA treatment By Investing.com - Investing.com South Africa
LXEO files 41.6M-share prospectus; $80M raise backs accelerated LX2006 plan | ATNFW SEC FilingForm 8-K - Stock Titan
LXEO files 41.6M-share prospectus; $80M raise backs accelerated LX2006 plan - Stock Titan
Lexeo Therapeutics stockholders elect directors and ratify auditor at annual meeting - Investing.com
Lexeo Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks
Lexeo Therapeutics, Inc.(NasdaqGM: LXEO) dropped from Russell 2000 Growth Index - MarketScreener
Lexeo Therapeutics, PXV Funds and venBio launch new entity to advance RNA therapies for cardiac diseases - Pharmafile
Lexeo Therapeutics Partners with PXV Funds, venBio on New Cardiac RNA Therapeutics Venture - MarketScreener
Bank of America Corp DE Trims Stock Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics files to sell 41.63M shares of common stock for holders - MSN
Lexeo Therapeutics (LXEO) Proposes Sale of 41.63 Million Shares - GuruFocus
Lexeo Therapeutics Registers Share Offering on Behalf of Selling Stockholders - MarketScreener
Lexeo Therapeutics (LXEO) Proposes Sale of 41.63 Million Shares | LXEO Stock News - GuruFocus
Jane Street Group LLC Reduces Stock Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Finanzdaten der Lexeo Therapeutics Inc-Aktie (LXEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):